Kate Bubar
Postdoctoral Scholar, Infectious Diseases
Bio
Kate is a postdoc in the Lo Lab. With a background in applied mathematics, statistics, and infectious disease epidemiology, she is passionate about using data-driven models to better understand infectious disease dynamics with the ultimate goal of informing public health policies and reducing disease burden.
Professional Education
-
Doctor of Philosophy, University of Colorado Boulder (2024)
-
Bachelor of Science, Colorado School of Mines (2019)
-
Master of Science, University of Colorado Boulder (2022)
All Publications
-
Epidemiologic shifts predict spatial patterns of measles re-emergence in the United States.
medRxiv : the preprint server for health sciences
2026
Abstract
Globally, measles is re-emerging in countries that have previously achieved elimination, including the United States. As immunization rates decline, characterizing the dynamics and evolving spatial pattern of measles re-emergence is critical to inform the public health response. We analyze annual county-level measles cases and vaccine coverage data in the United States (US) from 2011-2025 and find a shift in measles epidemiology in recent years indicative of re-emergence. While outbreak risk is spatially concentrated, we find that outbreaks are increasingly spreading throughout the broader population and across counties, but targeted interventions are predicted to prevent re-emergence nationwide. During the first decade of this period (2011-2020), outbreaks were only weakly associated with county-level vaccine coverage and predominantly isolated to single counties; however, recently (2021-2025), vaccine coverage has become strongly associated with outbreak size and spread across neighboring counties has increased. These findings suggest that measles transmission is increasingly sustained across the broader population rather than only in socially clustered communities. We developed a spatial statistical model to predict outbreak risk and size in all US counties with validation over 2021-2025; the model predicted counties with ≥10 cases with a sensitivity of 95% (range across 2021-2025: 75-100%) and specificity of 83% (64-98%). Mechanistic models based on county vaccine coverage alone had worse performance, particularly in predicting larger outbreaks. Using the spatial statistical model, we find that prioritizing interventions in the areas of greatest model-predicted risk (e.g., top decile of US counties) was more impactful than state-level interventions (e.g., top five states) or targeting based on low vaccine coverage alone. Achieving even modest (5 percentage point) increases in vaccine coverage in counties in the top decile of model-predicted risk reduced long-term measles risk nationwide by over 90%. Together, these findings demonstrate that predictive risk modeling to inform spatially targeted interventions can likely mitigate the re-emergence of vaccine-preventable diseases.
View details for DOI 10.64898/2026.10.14.26365590
View details for PubMedID 42947685
View details for PubMedCentralID PMC13701098
-
Rethinking seasonal COVID-19 vaccination in the endemic era: summer timing, eligibility, and frequency in the United States.
medRxiv : the preprint server for health sciences
2026
Abstract
With a recent shift towards summer seasonal predominance of COVID-19 across much of the US, debate continues over optimal COVID-19 vaccination strategies regarding timing (including summer vaccination), eligibility, and dosing frequency. We evaluated the population-level impact of alternative vaccine strategies to inform US and state vaccine policy.To compare reductions in COVID-19 hospitalizations under different vaccination timing, eligibility, and dosing frequency.Decision analytical model using a stochastic individual-based model of SARS-CoV-2 transmission, calibrated to US COVID-19 hospitalization incidence from May 2024-April 2025.Simulated US national population, with additional scenarios representing state-level seasonal patterns.Simulated population of 5 million individuals with US age structure, stratified by risk group (immunocompetent, high risk with comorbid conditions, or immunocompromised).Vaccination timing, universal or age- and risk-based eligibility, and dosing frequency, including a hybrid strategy of universal annual vaccination with a second dose for adults ≥65 years and immunocompromised adults (US vaccine policy during the study period).COVID-19 hospitalization risk per 100,000 persons by age-risk group, measured among vaccinated individuals and in the total population.If summer COVID-19 vaccination timing is feasible, annual universal vaccination in July minimized risk (441 [95% UI: 423-463] COVID-19 hospitalizations per 100,000 persons among adults ≥65 years) compared to a counterfactual scenario with no additional vaccination given during the study period (578 [553-601]). If timing does not change, hybrid vaccination minimized risk, followed by semiannual risk-based vaccination (460 [440-487] and 477 [454-499] hospitalizations per 100,000 in adults ≥65 years, respectively). The advantage of summer timing diminished if vaccine coverage decreased by 5-10 absolute percentage points (25-50% relative decrease). The magnitude of benefit from summer-timed vaccination and semiannual doses in the highest-risk groups varied regionally.Although annual COVID-19 vaccination has historically been timed for winter transmission, summer vaccination may avert more hospitalizations if coverage is maintained, especially in states with predominantly summer transmission including Western and Southern states. The comparative impact of vaccination strategies, especially the benefit of a semiannual dose in the highest-risk groups, may vary regionally. COVID-19 vaccination timing and eligibility may warrant reconsideration.
View details for DOI 10.64898/2026.09.23.26363810
View details for PubMedID 42818532
View details for PubMedCentralID PMC13622440
-
Trends in County-Level Childhood Vaccination Exemptions in the US.
JAMA
2026
View details for DOI 10.1001/jama.2025.24407
View details for PubMedID 41533386
View details for PubMedCentralID PMC12805488
-
Modeling Reemergence of Vaccine-Eliminated Infectious Diseases Under Declining Vaccination in the US.
JAMA
2025
Abstract
Widespread childhood vaccination has eliminated many infectious diseases in the US. However, vaccination rates are declining, and there are ongoing policy debates to reduce the childhood vaccine schedule, which may risk reemergence of previously eliminated infectious diseases.To estimate the number of cases and complications in the US under scenarios of declining childhood vaccination for measles, rubella, poliomyelitis, and diphtheria.A simulation model was used to assess the importation and dynamic spread of vaccine-preventable infectious diseases across 50 US states and the District of Columbia. The model was parameterized with data on area-specific estimates for demography, population immunity, and infectious disease importation risk. The model evaluated scenarios with different vaccination rates over a 25-year period. Inputs for current childhood vaccination rates were based on 2004-2023 data.The primary outcomes were estimated cases of measles, rubella, poliomyelitis, and diphtheria in the US. The secondary outcomes were estimated rates of infection-related complications (postmeasles neurological sequelae, congenital rubella syndrome, paralytic poliomyelitis, hospitalization, and death) and the probability and timing for an infection to reestablish endemicity.At current state-level vaccination rates, the simulation model predicts measles may reestablish endemicity (83% of simulations; mean time of 20.9 years) with an estimated 851 300 cases (95% uncertainty interval [UI], 381 300 to 1.3 million cases) over 25 years. Under a scenario with a 10% decline in measles-mumps-rubella (MMR) vaccination, the model estimates 11.1 million (95% UI, 10.1-12.1 million) cases of measles over 25 years, whereas the model estimates only 5800 cases (95% UI, 3100-19 400 cases) with a 5% increase in MMR vaccination. Other vaccine-preventable diseases are unlikely to reestablish endemicity under current levels of vaccination. If routine childhood vaccination declined by 50%, the model predicts 51.2 million (95% UI, 49.7-52.5 million) cases of measles over a 25-year period, 9.9 million (95% UI, 6.4-13.0 million) cases of rubella, 4.3 million cases (95% UI, 4 cases to 21.5 million cases) of poliomyelitis, and 197 cases (95% UI, 1-1000 cases) of diphtheria. Under this scenario, the model predicts 51 200 cases (95% UI, 49 600-52 600 cases) with postmeasles neurological sequelae, 10 700 cases (95% UI, 6700-14 600 cases) of congenital rubella syndrome, 5400 cases (95% UI, 0-26 300 cases) of paralytic poliomyelitis, 10.3 million hospitalizations (95% UI, 9.9-10.5 million hospitalizations), and 159 200 deaths (95% UI, 151 200-164 700 deaths). In this scenario, measles became endemic at 4.9 years (95% UI, 4.3-5.6 years) and rubella became endemic at 18.1 years (95% UI, 17.0-19.6 years), whereas poliovirus returned to endemic levels in about half of simulations (56%) at an estimated 19.6 years (95% UI, 14.0-24.7 years). There was large variation across the US population.Based on estimates from this modeling study, declining childhood vaccination rates will increase the frequency and size of outbreaks of previously eliminated vaccine-preventable infections, eventually leading to their return to endemic levels. The timing and critical threshold for returning to endemicity will differ substantially by disease, with measles likely to be the first to return to endemic levels and may occur even under current vaccination levels without improved vaccine coverage and public health response. These findings support the need to continue routine childhood vaccination at high coverage to prevent resurgence of vaccine-preventable infectious diseases in the US.
View details for DOI 10.1001/jama.2025.6495
View details for PubMedID 40272967
-
SARS-CoV-2 transmission and impacts of unvaccinated-only screening in populations of mixed vaccination status.
Nature communications
2022; 13 (1): 2777
Abstract
Screening programs that test only the unvaccinated population have been proposed and implemented to mitigate SARS-CoV-2 spread, implicitly assuming that the unvaccinated population drives transmission. To evaluate this premise and quantify the impact of unvaccinated-only screening programs, we introduce a model for SARS-CoV-2 transmission through which we explore a range of transmission rates, vaccine effectiveness scenarios, rates of prior infection, and screening programs. We find that, as vaccination rates increase, the proportion of transmission driven by the unvaccinated population decreases, such that most community spread is driven by vaccine-breakthrough infections once vaccine coverage exceeds 55% (omicron) or 80% (delta), points which shift lower as vaccine effectiveness wanes. Thus, we show that as vaccination rates increase, the transmission reductions associated with unvaccinated-only screening decline, identifying three distinct categories of impact on infections and hospitalizations. More broadly, these results demonstrate that effective unvaccinated-only screening depends on population immunity, vaccination rates, and variant.
View details for DOI 10.1038/s41467-022-30144-7
View details for PubMedID 35589681
View details for PubMedCentralID PMC9120147
-
Implications of Test Characteristics and Population Seroprevalence on "Immune Passport" Strategies
CLINICAL INFECTIOUS DISEASES
2021; 72 (9): E412-E414
View details for DOI 10.1093/cid/ciaa1019
View details for Web of Science ID 000757528700036
-
Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys.
eLife
2021; 10
Abstract
Establishing how many people have been infected by SARS-CoV-2 remains an urgent priority for controlling the COVID-19 pandemic. Serological tests that identify past infection can be used to estimate cumulative incidence, but the relative accuracy and robustness of various sampling strategies have been unclear. We developed a flexible framework that integrates uncertainty from test characteristics, sample size, and heterogeneity in seroprevalence across subpopulations to compare estimates from sampling schemes. Using the same framework and making the assumption that seropositivity indicates immune protection, we propagated estimates and uncertainty through dynamical models to assess uncertainty in the epidemiological parameters needed to evaluate public health interventions and found that sampling schemes informed by demographics and contact networks outperform uniform sampling. The framework can be adapted to optimize serosurvey design given test characteristics and capacity, population demography, sampling strategy, and modeling approach, and can be tailored to support decision-making around introducing or removing interventions.
View details for DOI 10.7554/eLife.64206
View details for PubMedID 33666169
View details for PubMedCentralID PMC7979159
-
Model-informed COVID-19 vaccine prioritization strategies by age and serostatus.
Science (New York, N.Y.)
2021; 371 (6532): 916-921
Abstract
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
View details for DOI 10.1126/science.abe6959
View details for PubMedID 33479118
View details for PubMedCentralID PMC7963218
-
Advances in stable isotope tracer methodology part 1: hepatic metabolism via isotopomer analysis and postprandial lipolysis modeling.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research
2020; 68 (1): 3-10
Abstract
Stable isotope tracers have been used to gain an understanding of integrative animal and human physiology. More commonly studied organ systems include hepatic glucose metabolism, lipolysis from adipose tissue, and whole body protein metabolism. Recent improvements in isotope methodology have included the use of novel physiologic methods/models and mathematical modeling of data during different physiologic states. Here we review some of the latest advancements in this field and highlight future research needs. First we discuss the use of an oral [U-13C3]-glycerol tracer to determine the relative contribution of glycerol carbons to hepatic glucose production after first cycling through the tricarboxylic acid cycle, entry of glycerol into the pentose phosphate pathway or direct conversion of glycerol into the glucose. Second, we describe an adaptation of the established oral minimal model used to define postprandial glucose dynamics to include glycerol dynamics in an oral glucose tolerance test with a [2H5]-glycerol tracer to determine dynamic changes in lipolysis. Simulation results were optimized when parameters describing glycerol flux were determined with a hybrid approach using both tracer-based calculations and constrained parameter optimization. Both of these methodologies can be used to expand our knowledge of not only human physiology, but also the effects of various nutritional strategies and medications on metabolism.
View details for DOI 10.1136/jim-2019-001109
View details for PubMedID 31554675
View details for PubMedCentralID PMC7372575
-
Morning Circadian Misalignment Is Associated With Insulin Resistance in Girls With Obesity and Polycystic Ovarian Syndrome.
The Journal of clinical endocrinology and metabolism
2019; 104 (8): 3525-3534
Abstract
To our knowledge, circadian rhythms have not been examined in girls with polycystic ovarian syndrome (PCOS), despite the typical delayed circadian timing of adolescence, which is an emerging link between circadian health and insulin sensitivity (SI), and decreased SI in PCOS.To examine differences in the circadian melatonin rhythm between obese adolescent girls with PCOS and control subjects, and evaluate relationships between circadian variables and SI.Cross-sectional study.Obese adolescent girls with PCOS (n = 59) or without PCOS (n = 33).Estimated sleep duration and timing from home actigraphy monitoring, in-laboratory hourly sampled dim-light, salivary-melatonin and fasting hormone analysis.All participants obtained insufficient sleep. Girls with PCOS had later clock-hour of melatonin offset, later melatonin offset relative to sleep timing, and longer duration of melatonin secretion than control subjects. A later melatonin offset after wake time (i.e., morning wakefulness occurring during the biological night) was associated with higher serum free testosterone levels and worse SI regardless of group. Analyses remained significant after controlling for daytime sleepiness and sleep-disordered breathing.Circadian misalignment in girls with PCOS is characterized by later melatonin offset relative to clock time and sleep timing. Morning circadian misalignment was associated with metabolic dysregulation in girls with PCOS and obesity. Clinical care of girls with PCOS and obesity would benefit from assessment of sleep and circadian health. Additional research is needed to understand mechanisms underlying the relationship between morning circadian misalignment and SI in this population.
View details for DOI 10.1210/jc.2018-02385
View details for PubMedID 30888398
View details for PubMedCentralID PMC6610211